ReviewFuture oncology (London, England)2025

Enfortumab vedotin and pembrolizumab: redefining the standard of care for previously untreated advanced urothelial cancer.

Michal Sternschuss et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.